R P G van Heeswijk
Overview
Explore the profile of R P G van Heeswijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Heeswijk R, Dannemann B, Hoetelmans R
J Antimicrob Chemother
. 2014 May;
69(9):2310-8.
PMID: 24860154
Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4...
2.
la Porte C, Li Y, Beique L, Foster B, Chauhan B, Garber G, et al.
Clin Pharmacol Ther
. 2007 Mar;
82(4):389-95.
PMID: 17361121
This genotype panel study investigated the effect of ABCB1 polymorphism in exon 26 (C3435T), exon 21 (G2677T/A), and exon 12 (C1236T) on saquinavir pharmacokinetics and on the expression and activity...
3.
Cooper C, van Heeswijk R
HIV Med
. 2007 Feb;
8(1):1-7.
PMID: 17305925
In the context of attempts to simplify treatment regimens and enhance adherence, there is great interest in once-daily dosing regimens for the treatment of HIV-1 infection. Nevirapine has a long...
4.
van Heeswijk R, Bourbeau M, Seguin I, Giguere P, Garber G, Cameron D
Br J Clin Pharmacol
. 2005 Apr;
59(4):398-404.
PMID: 15801934
Aims: To compare the pharmacokinetics of lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the morning compared with the evening. Methods: This was a randomized, two-way, cross-over study in HIV+...
5.
Cooper C, van Heeswijk R, Gallicano K, Cameron D
Clin Infect Dis
. 2003 Jun;
36(12):1585-92.
PMID: 12802760
The pharmacokinetics of protease inhibitors center around the microsomal enzyme cytochrome P-450 3A4. As a potent inhibitor of this enzyme, ritonavir can increase the bioavailability and half-life of coadministered protease...